Organization | Ev. Krankenhaus Essen-Werden

Ev. Krankenhaus Essen-Werden Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

1999

NCT00209833

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Alternative names

Dr. Stefan Esser, Essen | Dr. Thomas Lutz, Frankfurt/M

Active Ingredients

Drugs in Phase 4 Trials (3)

atazanavir (reyataz) (1 trial)

raltegravir (isentress) (1 trial)

ritonavir (Norvir) (1 trial)

Drugs in Phase 3 Trials (6)

cytarabine (cytosar-u) (1 trial)

daunorubicin (cerubidine) (1 trial)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (1 trial)

idarubicin (idamycin) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia, Refractory (Phase 3)

Anemia, Refractory, with Excess of Blasts (Phase 3)

Hepatitis C (Phase 4)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Neoplasm Metastasis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 9